Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Current Assets: 2017-2025

Historic Current Assets for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to $442.8 million.

  • Cidara Therapeutics' Current Assets rose 182.46% to $442.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $442.8 million, marking a year-over-year increase of 182.46%. This contributed to the annual value of $210.7 million for FY2024, which is 246.29% up from last year.
  • Per Cidara Therapeutics' latest filing, its Current Assets stood at $442.8 million for Q3 2025, which was down 16.73% from $531.8 million recorded in Q2 2025.
  • In the past 5 years, Cidara Therapeutics' Current Assets ranged from a high of $531.8 million in Q2 2025 and a low of $36.5 million during Q2 2022.
  • Moreover, its 3-year median value for Current Assets was $156.8 million (2024), whereas its average is $182.6 million.
  • As far as peak fluctuations go, Cidara Therapeutics' Current Assets crashed by 41.32% in 2024, and later soared by 303.23% in 2025.
  • Cidara Therapeutics' Current Assets (Quarterly) stood at $71.7 million in 2021, then plummeted by 37.11% to $45.1 million in 2022, then surged by 34.95% to $60.9 million in 2023, then soared by 246.29% to $210.7 million in 2024, then spiked by 182.46% to $442.8 million in 2025.
  • Its Current Assets stands at $442.8 million for Q3 2025, versus $531.8 million for Q2 2025 and $188.8 million for Q1 2025.